Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T03346 | ||||
Target Name | Interleukin-4 receptor alpha | ||||
Synonyms | CD124 antigen; IL-4R; IL-4R-alpha; IL4R | ||||
Target Type | Successful | ||||
Gene Name | IL4R | ||||
Biochemical Class | Cytokine receptor | ||||
UniProt ID | IL4RA_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Atopic dermatitis | ||||
Example drug | Dupilumab | Approved | [1], [2] | ||
Tissue | Skin | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.76 Z-score: 3.74 P-value: 1.48E-08 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Asthma | ||||
Example drug | SAR231893 | Phase 3 | [3], [2] | ||
Tissue | Nasal and bronchial airway | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.16 Z-score: 0.37 P-value: 1.02E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Idiopathic pulmonary fibrosis | ||||
Example drug | SAR-156597 | Phase 2 | [4], [2] | ||
Tissue | Lung tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.59 Z-score: -1.29 P-value: 6.07E-02 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
![]() |
|||||
Reference | |||||
REF 1 | Drugs@FDA (Edaravone) | ||||
REF 2 | NCBI GEO: archive for functional genomics data sets--update. | ||||
REF 3 | ClinicalTrials.gov (NCT02134028) Long-Term Safety Evaluation of Dupilumab in Patients With Asthma. U.S. National Institutes of Health. | ||||
REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034106) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.